Search
PARPI F-18
go.drugbank.com/drugs/DB18657ExperimentalPARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme.
Ivonescimab
go.drugbank.com/drugs/DB18931InvestigationalIvonescimab is under investigation in clinical trial NCT05184712 (Phase 3 Clinical Study of AK112 for NSCLC Patients).
Aminoflavone
go.drugbank.com/drugs/DB19077InvestigationalAminoflavone is under investigation in clinical trial NCT01015521 (Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer).
Lactide, L-
go.drugbank.com/drugs/DB19115InvestigationalLactide, L- is under investigation in clinical trial NCT05450471 (Effectiveness of Endonasal Polymeric Implant for Chronic Rhinosinusitis).
NSI-189
go.drugbank.com/drugs/DB16230InvestigationalNSI-189 is under investigation in clinical trial NCT02695472 (Study of NSI-189 for Major Depressive Disorder).
Enviomycin
go.drugbank.com/drugs/DB08993ExperimentalIt is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.
Synonyms: Tuberactinomycin NAnzurstobart
go.drugbank.com/drugs/DB17547InvestigationalIt is being investigated for cancers. … Anzurstobart is a monoclonal antibody directed against signal-regulatory protein alpha (SIRPα) on monocytes and macrophages to potently block the CD47-SIRPα interaction.
Actinium Ac 225 dotatate
go.drugbank.com/drugs/DB23632InvestigationalActinium Ac 225 dotatate is under investigation in clinical trial NCT07150806 (RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma). … Actinium Ac 225 dotatate is a biologic drug.
FT-1101
go.drugbank.com/drugs/DB17553Investigational[A257301] FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies). … FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor.
Inaxaplin
go.drugbank.com/drugs/DB21521InvestigationalInaxaplin is under investigation in clinical trial NCT06794996 (Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease). … Inaxaplin is a small molecule drug.